Literature DB >> 19762228

Contemporary pre-clinical development of anticancer agents--what are the optimal preclinical models?

Giovanna Damia1, Maurizio D'Incalci.   

Abstract

The successful identification of novel effective anticancer drugs is largely dependent on the use of appropriate preclinical experimental models that should possibly mimic the complexity of different cancer diseases. The huge number of targets suitable for the design of new anticancer drugs is producing hundreds of novel molecules that require appropriate experimental models to investigate their mode of action and antitumour activity in order to select for clinical investigation the ones with higher chances of being clinically effective. However, our ability to predict the clinical efficacy of a new compound in the clinic based on preclinical data is still limited. This paper overviews the in vitro/in vivo preclinical systems that are currently used to test either compounds with an unknown mechanism of action or compounds designed to hit cancer-specific or cancer-related molecular targets. Examples of experimental models successfully used to identify novel compounds are provided. Xenografts are still the most commonly used in vivo models in drug development due to their high degree of reproducibility and because, in some cases, particularly when orthotopically transplanted, they maintain several biological properties of the human tumours they derive from. Genetic models are very useful for target validation, but are often not sufficiently reproducible to be used for drug evaluation. The variety of animal models can be effectively used to optimally test drugs that presumably act by a defined mode of action, but final success is highly dependent on the ability of drug development teams to integrate different expertises such as biology, chemistry, pharmacology, toxicology and clinical oncology into a clever and well orchestrated plan that keeps in consideration both the complexity of cancer diseases, involving alterations of different pathways, and the complexity of drugs whose pharmacological properties are crucial to obtain the desired effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762228     DOI: 10.1016/j.ejca.2009.08.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

Review 1.  Emerging applications of metabolomics in studying chemopreventive phytochemicals.

Authors:  Lei Wang; Chi Chen
Journal:  AAPS J       Date:  2013-06-22       Impact factor: 4.009

Review 2.  Analysis on the current status of targeted drug delivery to tumors.

Authors:  Il Keun Kwon; Sang Cheon Lee; Bumsoo Han; Kinam Park
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

3.  Targeted drug delivery to tumors: myths, reality and possibility.

Authors:  You Han Bae; Kinam Park
Journal:  J Control Release       Date:  2011-06-06       Impact factor: 9.776

Review 4.  Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip.

Authors:  Bumsoo Han; Chunjing Qu; Kinam Park; Stephen F Konieczny; Murray Korc
Journal:  Cancer Lett       Date:  2015-12-10       Impact factor: 8.679

5.  Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies.

Authors:  Thomas Poeschinger; Anja Renner; Thomas Weber; Werner Scheuer
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

6.  Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research.

Authors:  David H Lum; Cindy Matsen; Alana L Welm; Bryan E Welm
Journal:  Curr Protoc Pharmacol       Date:  2012-12

7.  Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.

Authors:  Arvind K Singla; Alla Bondareva; Frank R Jirik
Journal:  Clin Exp Metastasis       Date:  2014-06-26       Impact factor: 5.150

8.  Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Authors:  Robert E Martell; David Sermer; Kenneth Getz; Kenneth I Kaitin
Journal:  Oncologist       Date:  2012-12-20

Review 9.  Nanoparticle characterization: state of the art, challenges, and emerging technologies.

Authors:  Eun Jung Cho; Hillary Holback; Karen C Liu; Sara A Abouelmagd; Joonyoung Park; Yoon Yeo
Journal:  Mol Pharm       Date:  2013-03-21       Impact factor: 4.939

10.  Simulation of complex transport of nanoparticles around a tumor using tumor-microenvironment-on-chip.

Authors:  Bongseop Kwak; Altug Ozcelikkale; Crystal S Shin; Kinam Park; Bumsoo Han
Journal:  J Control Release       Date:  2014-09-03       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.